Differences in virological response to peginterferon-α plus ribavirin in HIV-positive patients coinfected with HCV subtypes 1a or 1b
BACKGROUND: Both viral and host factors influence response to peginterferon-α plus ribavirin (pegIFNα/RBV) in patients with chronic hepatitis C. The impact of these variables is more pronounced in HIV/Hepatitis C virus (HCV)-coinfected individuals, in whom treatment response rates are lower.
METHODS: Virological responses at multiple time points were assessed in all HIV/HCV-coinfected patients that completed a first course of pegIFNα/RBV. Viral responses were stratified by HCV geno/subtypes and IL28B rs12979860 variants.
RESULTS: A total of 331 HIV/HCV-coinfected patients were analyzed. HCV geno/subtype distribution was as follows: HCV-1a in 97, HCV-1b in 62, HCV-3 in 122, and HCV-4 in 50. Age, gender, CD4 counts, plasma HIV RNA and liver fibrosis stage did not differ significantly across HCV geno/subtypes. In contrast, mean serum HCV RNA was greater in HCV-1a compared with the rest (P < 0.0001). The proportion of IL28B CC variants was higher in HCV-3 compared with the rest (P = 0.001). Virological responses were better in HCV-1b than HCV-1a at any given time point during therapy. IL28B variants significantly influenced virological responses across all HCV-1 subtypes, with the strongest effect seen in HCV-1a. In a multivariate linear regression analysis, both HCV-1b and IL28B CC variants were significantly associated with greater HCV RNA drops at weeks 4 (R = 0.52, p < 0.0001) and 12 (R = 0.49, P < 0.0001) of therapy.
CONCLUSIONS: The response to pegIFNα/RBV therapy is lower in HCV-1a than HCV-1b in HIV/HCV-coinfected patients. The strongest influence of IL28B variants is seen in HCV-1a. This information may be relevant when using most directly acting antivirals in coinfected patients along with pegIFNα/RBV, given that selection of drug resistance occurs more frequently in HCV-1a than HCV-1b.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:60 |
|---|---|
| Enthalten in: |
Journal of acquired immune deficiency syndromes (1999) - 60(2012), 2 vom: 01. Juni, Seite 117-23 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rallón, Norma I [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 25.07.2012 Date Revised 30.09.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/QAI.0b013e31824f5506 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM215687612 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM215687612 | ||
| 003 | DE-627 | ||
| 005 | 20231224030020.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/QAI.0b013e31824f5506 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0719.xml |
| 035 | |a (DE-627)NLM215687612 | ||
| 035 | |a (NLM)22362153 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rallón, Norma I |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Differences in virological response to peginterferon-α plus ribavirin in HIV-positive patients coinfected with HCV subtypes 1a or 1b |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.07.2012 | ||
| 500 | |a Date Revised 30.09.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Both viral and host factors influence response to peginterferon-α plus ribavirin (pegIFNα/RBV) in patients with chronic hepatitis C. The impact of these variables is more pronounced in HIV/Hepatitis C virus (HCV)-coinfected individuals, in whom treatment response rates are lower | ||
| 520 | |a METHODS: Virological responses at multiple time points were assessed in all HIV/HCV-coinfected patients that completed a first course of pegIFNα/RBV. Viral responses were stratified by HCV geno/subtypes and IL28B rs12979860 variants | ||
| 520 | |a RESULTS: A total of 331 HIV/HCV-coinfected patients were analyzed. HCV geno/subtype distribution was as follows: HCV-1a in 97, HCV-1b in 62, HCV-3 in 122, and HCV-4 in 50. Age, gender, CD4 counts, plasma HIV RNA and liver fibrosis stage did not differ significantly across HCV geno/subtypes. In contrast, mean serum HCV RNA was greater in HCV-1a compared with the rest (P < 0.0001). The proportion of IL28B CC variants was higher in HCV-3 compared with the rest (P = 0.001). Virological responses were better in HCV-1b than HCV-1a at any given time point during therapy. IL28B variants significantly influenced virological responses across all HCV-1 subtypes, with the strongest effect seen in HCV-1a. In a multivariate linear regression analysis, both HCV-1b and IL28B CC variants were significantly associated with greater HCV RNA drops at weeks 4 (R = 0.52, p < 0.0001) and 12 (R = 0.49, P < 0.0001) of therapy | ||
| 520 | |a CONCLUSIONS: The response to pegIFNα/RBV therapy is lower in HCV-1a than HCV-1b in HIV/HCV-coinfected patients. The strongest influence of IL28B variants is seen in HCV-1a. This information may be relevant when using most directly acting antivirals in coinfected patients along with pegIFNα/RBV, given that selection of drug resistance occurs more frequently in HCV-1a than HCV-1b | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Interferon-alpha |2 NLM | |
| 650 | 7 | |a Recombinant Proteins |2 NLM | |
| 650 | 7 | |a Polyethylene Glycols |2 NLM | |
| 650 | 7 | |a 3WJQ0SDW1A |2 NLM | |
| 650 | 7 | |a Ribavirin |2 NLM | |
| 650 | 7 | |a 49717AWG6K |2 NLM | |
| 650 | 7 | |a peginterferon alfa-2a |2 NLM | |
| 650 | 7 | |a Q46947FE7K |2 NLM | |
| 700 | 1 | |a Pineda, Juan A |e verfasserin |4 aut | |
| 700 | 1 | |a Soriano, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Neukam, Karin |e verfasserin |4 aut | |
| 700 | 1 | |a Vispo, Eugenia |e verfasserin |4 aut | |
| 700 | 1 | |a Rivero, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Labarga, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Caruz, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Restrepo, Clara |e verfasserin |4 aut | |
| 700 | 1 | |a Camacho, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Barreiro, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Benito, Jose M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of acquired immune deficiency syndromes (1999) |d 1999 |g 60(2012), 2 vom: 01. Juni, Seite 117-23 |w (DE-627)NLM101679912 |x 1944-7884 |7 nnns |
| 773 | 1 | 8 | |g volume:60 |g year:2012 |g number:2 |g day:01 |g month:06 |g pages:117-23 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/QAI.0b013e31824f5506 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 60 |j 2012 |e 2 |b 01 |c 06 |h 117-23 | ||